Information Provided By: 
Fly News Breaks for January 7, 2019
SAGE
Jan 7, 2019 | 08:13 EDT
After Sage Therapeutics reported top-line results from the Phase 3 ROBIN study in women with postpartum depression, or PPD, Piper Jaffray analyst Danielle Brill said the data were "impressive and looked clean across the board" in a note titled "Clear Win as SAGE-217 Knocks It Out of the PPD Park." The analyst, who expects over 50% upside for Sage shares today, keeps an Overweight rating on the stock with a $206 price target. In pre-market trading, Sage Therapeutics shares are up $34.49, or 35%, to $132.
News For SAGE From the Last 2 Days
There are no results for your query SAGE
